STOCKS TELEGRAPH

Author: ST Staff

  • UP Fintech Holding Inc. (TIGR) stock rises in the pre-market trading. Why is it so?

    UP Fintech Holding Inc. (TIGR) stock rises in the pre-market trading. Why is it so?

    UP Fintech Holding Inc. (TIGR) stock gained by 2.56% in the last trading close while the TIGR stock continued to rise in pre-market trading by 14.97% after UP Fintech announced its fourth quarter and full-year fiscal 2020 unaudited financial results. UP Fintech Holding is a well-known online brokerage firm that focuses on global investors. Investors can trade equities and other financial instruments on various exchanges around the world using TIGR’s advanced smartphone and online trading network.

    Financial Results

    • The total revenue generated for the fourth quarter of 2020 was US$47.2 million and US$138.5 million for the full fiscal year 2020. This is an increase of 136.5% and 136.1% compared to the fourth quarter and full year 2019.
    • TIGR’s total net revenue recorded for the fourth quarter 2020 was US$42.9 million while it was US$128.4 million for the full year 2020.
    • The net come of TIGR for the fourth quarter 2020 was US$9.4 million compared to negative US$0.2 million in the same quarter of 2019. And for the full year the net income was US$19.2 million from negative US$5.9 in 2019.
    • Net income attributable to UP Fintech also increased in the fourth quarter and full year of 2020 reported as US$8.5 million and US$16.1 million respectively. The values were negative US$0.6 million and negative US$6.6 million for the Q4 and full year 2019.

    What more?

    Also Tiger Trade, the flagship trading app of TIGR, has managed to create a confined trading, social networking, and financial media hub. TIGR continues to improve its brand image and retail client stickiness by introducing more investment resources and goods, such as a grey market for Hong Kong IPOs.

    The CEO of UP Fintech said that they are excited for the coming year because they are planning to continue to leverage their technical capabilities to create an integrated trading network for global clients with a robust product offering,

  • Entera Bio Ltd (ENTX) stock plunged in the pre-market trading session; Here’s what’s happening

    Entera Bio Ltd (ENTX) stock showed a positive movement by 8.7% in the recent trading session where the stock’s price was $4.00. It previously closed at $3.68. However, in the pre-market trading session, the stock plunged by 9% at the time of writing.

    Recent news related to Entera Bio comes in the form of another Bio-pharmaceutical company-Abeona Therapeutics recently announcing two new independent board members to its board of directors. One of the newly appointed members includes a member of the Board of Directors in Entera Bio (ENTX).

    Entera Ltd. (ENTX)’s core focus

    Entera Bio Ltd. is a biotech company that specifically focuses on delivering large molecule therapeutics through oral administration. This large molecule therapeutics is used in the base of clinically-unmet medical needs. Administration of injectable therapies is expensive as compared to oral therapies which is why the focus on the latter is more efficient and easily supplied. However, oral administration may come upon hurdles of high-exposure to open air contamination, poor absorption and lack of synthetic absorber for large molecule dosage. ENTX has set its sight to deal with these technicalities to bridge the gap.

    BOD member of ENTX has joined the Board committee of Abeona Therapeutics Ltd.

    The member of the Board of Directors in Entera (ENTX) who is now serving in the newly appointed chair of BOD in Abeona, is known by the name of Faith L. Charles. Ms. Charles has 30 years of experience in legal profession and has specifically served sciences based companies. She has worked with several such companies. In Entera her title is that of the member Audit Committee and Chair of the Compensation Committee. Furthermore her business conduct is always associated with that of a valuable insight provider of capital markets and expert in corporate governance.

    How is the overall outlook for ENTX stock?

    On 18th March, ENTX released the financial and operating results for the fourth quarter and Full Year ended 31 December, 2020.

    The highlights for its operational activities for the Full-Year 2020 are as such:

    • Entera (ENTX) had the approval of EB613 IND from the FDA, for the Treatment of Osteoporosis. This allows progress for initial U.S clinical trials.
    • Successfully achieved primary endpoint for phase 2 clinical trial of EB613
    • Data regarding and including Bone Mineral Density is expected in Q2:21
    • Amgen Collaboration is showing progress by further evaluation of molecules like GLP-2

    The financial results for its FY 2020 showed overall improvement with the only relative underperformances:

    • Revenues for 31, Dec FY 2020 were $365,000 compared to $236,000 for 31, Dec FY 2019
    • Operating expenses were $11.3 million for 31, Dec FY 2020 as compared to $11.5 million for 31, Dec FY 2019
    • R&D expenses were $6.4 million for FY 2020 compared to $7.2 million for FY 2019
    • General administrative expenses were $4.9 million for 31, Dec FY 2020 compared to $4.3 million in 31, Dec FY 2019
    • Cash and cash equivalents were equal to $8.6 million at the end of FY 2020 compared to $15.2 million in 31, Dec FY 2019

    Entera (ENTX) consists of a lot of clinical trials in the pipelines that are showing progress. The continued advances in these trials will give the operational outcomes a boost for ENTX stock in the year 2021. These operational outcomes can then be further reflected on its financial activity health.

  • Why Vuzix Corporation (VUZI) Stock Was Up and Then Down Today

    Why Vuzix Corporation (VUZI) Stock Was Up and Then Down Today

    Vuzix Corporation (NASDAQ: VUZI) stock recently traded at $26.32 which is a 14.19% upward movement. The VUZI stock previously closed at $23.05. However, in the after-hours trading session, VUZI plunged by 12.99% at the time of writing.

    The recent negative movement in the stock comes adjacent to the announcement made by Vuzix for proposing of an underwritten public offering of common stock.

    Vuzix is a leading supplier of Smart Glasses

    Vuzix(VUZI) is a consumer electronics company specifically focusing on Augmented Reality technologies. It is a lead supplier of Smart Glasses that can automatically provide the wearer information on the focused object seen through the Smart Glasses. The glasses can also make facial recognitions, offer a high-quality viewing experience, and provide maps for mobility and wearable augmented display. All of Vuzix’s AR tech products are patented or in the process of being patented which becomes a total of 184.

    What could prompt VUZI stock to propose underwritten public offering?

    Vuzix Corporation (VUZI) announced today that it is planning to offer its shares of common stock for a sale proposal in the manner of the underwritten public offering. In this offering, the shareholder and investor can exercise the Company –given right to have a 30-day option for purchasing up to an additional 15% of the number of shares. These additional shares will be issued and sold in the same underwritten conditions and terms.

    The reason for this proposal is because the company will use the net proceeds for its expansion and operational growth; accelerating production of finished goods, acquisition of firms, R&D, and increasing workforce.

    Vuzix received a $250,000 order for M400 Smart Glasses

    Vuzix stock was already performing fundamentally strong; its overall outlook for 2021 shows financial and operational stability. This is especially true since the recent development that just came yesterday in the form of an initial smart glasses deployment order. This order came from a Healthcare and surgical training provider which totals an amount of $250,000 for Vuzix M400 Smart Glasses. These smart glasses will be used in the healthcare facility by surgeons, doctors, medical students, medical professors, and medtech experts.

    Healthcare industries are usually first to invest and adopt smart technology to enhance their ever-needed health facilities and provision optimum care to the patients. This is why Vuzix can expect to expand the orders of Vuzix M400 for the healthcare and medical training provider in the future.

    The path of growth ahead is clear for the Smart Glass supplier

    Vuzix stock is already showing a positive pattern due to the popularity of Vuzix M400 in the healthcare market since the past year. The additional stock offering could then suggest that the company is exceeding its initial projection of growth for 2021 and is going big. This is good news for investors even in the long run as Vuzix stock continues to soar.

  • Aspira Women’s Health, Inc. (AWH) stock soared today; here’s why it happened

    Aspira Women’s Health, Inc. (AWH) stock soared today; here’s why it happened

    Aspira Women’s Health Inc. (AWH) stock were rising 32.64% to trade at $8.9 in after-market at last check. The recent stock movement pattern comes adjacent to the news of the Aspira Women’s Health Inc. announcing their financial results for the fourth quarter and Full Year 2020 report.

    AWH’s stock gained 1.67% to close Thursday’s session at $6.71. The stock volume remained 1.48 million shares, which was higher than the average daily volume of 0.89 million shares within the past 50 days. AWH shares have risen by 852.31% over the last 12 months, and they have moved down by -10.89% in the past week. Over the past three months, the stock has gained 2.29%, while over the past six months, it has shed 164.17%. Further, the company has a current market of $761.79 million and its outstanding shares stood at 103.20 million.

    Overviews of Aspira’s operational fundamentals

    Aspira (AWH) is a bio-analytical healthcare company with 10 years of expertise in ovarian cancer detection, risk assessment, and treatment optimization. AWH specifically focuses on women hygiene and gynecologic diseases. Aspira is transforming the way women’s health is approached by providing testing options and bio-analytical solutions through innovation in discovering pattern, development, and commercialization. This overall helps the doctors and physicians analyze efficiently the risks and diagnoses for gynecologic diseases, and provide the optimum treatment and health management options for the patients.

    Recent developments and product offerings

    Aspira has created OVA1and OVERA and has commercialized its worldwide manufacturing for the detection of ovarian malignancy risk. The bio-analytical company has combined OVA1 and OVERA to produce OVA®1 plus which discovers the malignancy risks in adnexal masses for women. Aspira spends its money on research and development to produce risk assessment products for early-stage detection and treatment of diseases.

    The company has announced the revamping of speed of launch for the product OVASight. Furthermore, it has announced a strategic partnership/collaboration with Dana Farber Cancer Institute (DFCI).

    Aspira aspiring towards positive revenue and sales growth for 2021

    The CEO of Aspira’s statement regarding overall financial report suggests a positive growth in fundamentals despite pandemic, in terms of revenue, production volume, and financial stability.

    In terms of revenue Highlights;

    • The total revenue increased in fourth quarter 2020 to $1.41 million due to increased product volume. This is an 11% increase from $1.3 million of fourth quarter 2019.
    • The total revenue in the Full Year 2020 is $4.6 million which is a 5% increase from 2019.

    With regards to expansion of its operations, Aspira has announced that by 1st April, it will have coverage of New York State Medicaid that covers 33% population in the state. With this coverage, AWH will be covering 179 million lives which are roughly equal to 50% of the US population.

    Furthermore, the sales footprint also seem to get a solid hold in the stock market as on 8th February, another AWH common stock offering was completed. This offering resulted in the net proceeds approximating $48.4 million.

    Coverage expansion and partnership making way for growth in AWH stock

    Valerie Palmieri (CEO) stated that OVASight has been assigned the target launch date for the fourth quarter of 2021 while predicting that by 2022 it will have full national availability. The test is created uniquely to increase the base of the malignancy detection in women by specifically targeting the population with a low prevalence of the disease. An addition of 1.2 to 1.5 million women will incur in the base of malignancy detection.

    Along with DFCI, Aspira is also in collaboration with Brigham and Women’s Hospital, and Medical University Lodz to evaluate a combined technology product. This biotech combined product is for the development of a highly sensitive and specific (Proteomic and Transcriptomics) early detection test. It combines Aspira and the other healthcare firms’ microRNA technology to help doctors make an early assessments of high-risk ovarian cancer in women.

  • Kazia Therapeutics Limited (KZIA) stock soared in the after-hours trading session; find out why

    Kazia Therapeutics Limited (KZIA) stock soared in the after-hours trading session; find out why

    Kazia Therapeutics Limited (KZIA) stock recently plunged by 1.33% to trade at $11.12. It previously closed at $11.27. However, in the after-hours trading session, the KZIA stock soared higher than 24%.

    The stock movement pattern does not have any newly announced press release or expressed external factor motivating it. So why is there a surge in the after-hours trading session? For this we will have to connect the dots of the company’s previously announced news of licensing agreement as well as the type of ownership in the KZIA stock.

    Recent developments in KZIA stock

    Kazia Therapeutics Limited (KZIA) is a biotechnology company specifically focusing on innovative oncology. The company is based in Barangaroo, Australia. KZIA’s operational bases include working on developing therapies for numerous oncology indications. Furthermore, its lead program is known as paxalisib, which is being developed as a treatment for glioblastoma. Glioblastoma is the most aggressive and primary form of brain cancer in adults.

    Licensing agreement with the ovarian-cancer research expert Oasmia

    On 2nd March 2021, Kazia announced its exclusive worldwide agreement to license Cantrixil to Oasmia Pharmaceutical AB. Cantrixil is a clinical stage, uniquely innovated drug candidate that is being developed for the treatment of ovarian cancer.

    The agreement constitutes of Oasmia making a transactional payment of $4 million to Kazia, double digit royalties on commercial sales and upto $42 million payment on each progress completion milestone.

    Oasmia has worked over the years to harness deep expertise in the field of ovarian cancer and has worked on similar project of its own like Cantraxil which led to the development of lead product Apealea. Overall progress on the commercial production and development of Cantraxil is major forward step news since the clinical proof of the drug’s concept. This is solid clinical-stage progress on which investors can hedge their bets.

    How is type of shareholder influencing stock movement?

    Now let us focus on the investors and the type of shareholders who own KZIA stock.

    According to ownership breakdown, the institutions hold majority of the shares in the KZIA stock. This shows that the stock management is owner-oriented. When many institutions hold a fair amount of stake in a stock, it usually suggests that the company is well-established, major possibility of inside ownership and has a certain degree of credibility.

    While this could all turn to flip-side if the institutions altogether change their perspective or react to negative news about the company’s fundamental dynamics. But right now, mainly institutional and insider ownership is what is hinting towards the stock’s recent positive movement; it depicts that institutions are satisfied with the current leadership of the management and their preferences are being met.

  • Why You Should Keep An Eye Out For KE Holdings Inc (BEKE) Stock

    KE Holdings (BEKE), is China’s largest property technology company. The company has facilitated property transactions and add on services like financing for approximately two decades, however, it went public in august 2020, launching its IPO at $20 per stock.

    KE Holdings Inc opened at NYSE for $35 per share, $15 higher than its previous IPO. Since the launch, the share price has surged to a maximum of $79.40, depicting a 127% gain. Currently, the stock is set at $57 per share, valuing the company at $66.67B.

    BEKE’s Whopping Financials Has Peaked Potential Investments.

    In the third quarter of 2020, BEKE produced a gross transaction value of $154 billion, depicting an 87% increase year over year.The company Net profit margins went up by an impressive 211% to 1.9 billion yuan, surged by greater revenue and operating leverage.

    All three of BEKE’s business divisions, increased in revenue from current house transactions, new house transactions, and miscellaneous services rising 46%, 95%, and 117% year over year, respectively.

    Since the last two years, BEKE has tripled the number of agents associated with the company and is also currently set for expansion of its ancillary services options, including several financial products and building renovations. This should produce higher profit margins and complement BEKE’s fundamental business model. This will also help in the diversification ofBEKE’sincome stream, providing a gigantic financial surplus for the company.

    Conclusion

    In 2019 BEKE facilitated about 2.1 trillion yuan or 9% of all real estate transactions, making it China’s biggest property technology company. Providing a platform to match home buyers with real estate agents and brokers, as well as providing financial add-on services has proven to be extremely significant in increasing the company’s valuation. Furthermore, an approximate three-fold increase from its starting IPO value and diversification into several lucrative fields has peaked investor interest.

  • Koss Corporation (NASDAQ: KOSS) stock surged in the current market session today; Here’s why

    Koss Corporation’s (NASDAQ: KOSS) stock last closed at $16.42. The PIRS stock is currently trading at $21.58 and is up by 31.43% at this time of writing.

    The positive movement in the KOSS stock comes despites no press release by the company or any recent external actions motivating the stock movement.

    Koss Corporation (KOSS) revolutionized the electronic history

    Koss Corporation is a headphone manufacturing company in America. Koss Corporation was founded in 1958 by John C. Koss, and it revolutionized the way audio was heard around the world. The American headphone company designed the first-ever stereophone that came with the portable stereo phonograph player. In 1969, Koss Corporation provided the US president’s Air Force One plane with a Koss music and audio entertainment system.

    Past Performance of KOSS stock was not impressive

    In the ’80s and ’90s, the consumer electronics company’s business somewhat thrived, with the minor exception of 1984 where the company declared bankruptcy. This bankruptcy was due to the failure of diversification and expansion. However, after the bankruptcy, the KOSS stock’s performance stagnated throughout the trailing years.

    Is the recent hype worth a solid investment?

    All the low performance of the stock changed for a short period in January when it was tagged along in the retail investor frenzy caused by the WallStreetBets. The redditors had induced a short squeeze which took the KOSS stock up to $127.45 per share on January 8th. The stock did not sustain the hype and eventually fell back to below $20 per share two weeks later.

    However, the stock has seen some upward lift again recently. In the past month, its price dramatically increased over 70%, and on March 10th, its stock price had topped $40 per share. However, it is essential not to neglect the period before the Redditor-induced hype, where the prices were stagnant. Before January, the KOSS stock traded oscillated its movement between 1$-5$ for years.

    The KOSS Company’s operational performance is not as dull as its previous year’s stock performance; CEO Michael J. Koss had announced in a recent press release that the company is expanding its staff and workforce. The overall consumer electronics industry is predicted to see an annual growth rate of 20% throughout 2027, as researched by Grand View Research.

    Chance of repeating its performance history

    While the headphone manufacturing company is excelling on reviews for its Bluetooth and wireless category headphones, on Amazon, its lack of diversification is killing its potential profitable gains. The lack of diversification overshadows the bankruptcy it faced in 1984. The likes of Sony, Apple, and Samsung have established a full-spectrum of electronic gadgets and entertainment systems. This vastly increases their market share, while Koss only holds 1% of the market share.

    Overall outlook projects short-plays

    KOSS stock has only benefited from the short-squeezes despite its narrow-looking fundamental and operational outlook. But investors see the volatility of this stock to be a good swing trading play. All-in-all, the Koss stock barely provides any hopes for long-term investors, but the short-play possibilities are what draws attention from investors.

  • Pieris Pharmaceuticals Inc. (PIRS) stock has soared in the current session; Here’s why this is happening

    Pieris Pharmaceuticals Inc. (PIRS) stock has soared in the current session; Here’s why this is happening

    Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) stock last closed at $2.50. The PIRS stock is currently trading at $2.52 and is up by 0.40% at this time of writing.

    The current positive trend in the PIRS stock movement comes after the announcement by the clinical-stage biotechnology company of amendment in its collaboration with Seagen.

    The biotech company’s specific clinical-trial focus

    Pieris is a biotech company that specifically focuses its clinical-trial experiments on Anticalin protein-based drugs. The clinical stage company focuses on the developing and discovering of Anticalinto focus on targeting validated disease pathways in a way that is efficiently impactful. The company’s future and current treatment projects consist of respiratory diseases and immune-oncology multi-specifics associated with tumor.

    How does the amendment in agreement specifically change the collaboration?

    The amendment in the collaboration with Seagen in detail specifies Seagen’s strategic equity investment. This amendment in detail switches the option of development, promotion and commercialization rights of the existing immune-oncology agreement for the second of up to three products in the alliance. This investment has a purchasing price of $13 million in PIRS common stock. Total amount of stocks correlated to this investment will consist of 3,706,174 shares at the price of $3.51 per share.

    Furthermore the contractual reinstatements allow Pieris’ collaboration co-promotion option instead of co-development and co-commercialization of the project. At the same time, Seagen will solely be responsible for the development and commercialization of the project. Pieris can also increase its royalty if it chooses to implement this option.

    Both companies have also entered into a clinical trial collaboration agreement that will determine the efficacy of combining cinrebafuspalfa (PRS-343) with TUKYSA. PRS-343 is a 4-1BB/HER2 bispecific experiment of Pieris with Seagen’stucanib which is a small-molecule tyrosine kinase HER2 inhibitor. Both HER2 inhibitors are to be combined to test the treatment of gastric cancer patients that are depicting low HER2 levels. The safety of this test is also to be evaluated as part of Pieris’s upcoming phase 2 studies.

    The significance of this collaboration

    The significance of this combination of HER2 inhibitors is that it can address uniquely and specifically the patients with HER2 low expressing gastric cancer who do not respond to HER2-targeted therapies. Pieris lives up to its aim of combing and developing unique and innovative treatments for immune-oncology and respiratory diseases. In past, the PIRS stock went up due to similar collaboration and partnership announcements on projects with AstraZeneca, Servier and Seagen.

  • Oragenics Inc. (OGEN) stock rises 13% today. What’s happening?

    Oragenics Inc. (OGEN) stock rises 13% today. What’s happening?

    Oragenics Inc. (NASDAQ: OGEN) stock shows a gain of 13.57% in the current market trading session followed by no recent news regarding the rise of OGEN stock price. Oragenics focuses on the development of Terra CoV-2 vaccine to fight against the ongoing corona virus pandemic and also towards making efficient treatments for novel antibiotics against any infectious disease.

    Recent Developments

    On March 9, Oragenics announced that they have signed a material transfer agreement with Biodextris Inc. The purpose of the agreement is the use of three intranasal mucosal adjuvants in Terra CoV-2 vaccine introduced by OGEN for the treatment of COVID-19. To increase the efficiency of vaccines, Adjuvants are being added in them. BDX100, BDX300, and BDX301 are proteosome-based adjuvants made up of proteins and lipopolysaccharides that have boosted immune response, company productivity, and the ability to administer vaccines through intranasal ways.

    The three intranasal adjuvants will be used in conjunction with Oragenics’ antigen vaccine candidate in the preclinical immunological assessment of Terra CoV-2 for the risk reduction of coronavirus disease caused by an infection with the SARS-CoV-2 virus, according to the initial deal. It was also mentioned that the information that has been gathered through the studies after the implication of new intranasal vaccine candidate would be a support for U.S Food and Drug Administration FDA Investigational new drug application and also an application for Health Canada to start clinical trials.

    Lastly,

    It has been clarified in the agreement that Terra CoV-2 vaccine combined with Biodextris intranasal mucosal adjuvants will be under study in the following studies which are required for approval before testing the vaccine on humans.

    • preclinical animal studies
    • hamster viral challenge studies
    • mouse immunogenicity studies
    • rodent toxicology study

    Keeping this recent development in the account, it is possible that OGEN stock price is rising after this news.

  • Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Immutep Limited (IMMP) stock Rises over 40% today. Let’s find out why

    Shares of Immutep Limited (IMMP) stock were high in Thursday’s intraday trading after facing the downtrend of 5.73% at the last trade. IMMP stock price saw a surge of 43.33% today to reach $3.76 a share as of this writing.We find no particular activity by the IMMP stock to support this rise. Let’s deep dive to explore more of it.

    What’s happening?

    Immutep Limited (IMMP) is a biotechnology company focused on the research and development of immunotherapeutic products to treat cancer and autoimmune diseases. The rising stock price of IMMP has nothing to do with any specific announcement or press release by Immutep. However some investors believe that this gain is mainly due to the recent positive announcement by the Bristol Myers Squibb related to Phase 2/3 RELATIVITY-047, a trial related to Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab)

    Recent Announcements by IMMP stock.

    On March 16, 2021, IMMP announced the second trial and collaboration agreement with Merck & Co Inc in order to test its lead product for the treatment of the Second Head & Neck Cancer Study.According to this agreement, IMMP will perform a clinical trial called TACTI-003with160 patients of the 1st line head and neck squamous cell carcinoma (HNSCC).IMMP will observe the results by evaluating the efficacy and safety of its lead product eftilagimod alpha along with pembrolizumab, a Merck’s product.

    On March 09, 2021,Immutep secured the second United States patent grant for Eftilagimod Alpha and PD-1 pathway inhibitor which was filed as a  divisional application followed by the parent patent announced on December 30, 2020.This patent will expire on 20 January 2036 and will help in the clinical development programs of the Immutep in the future.

    Conclusion:

    Things are going well for the penny IMMP stock as far as market sentiment is concerned but the gain without any major reason usually doesn’t last for a long time.Investors having long-term prospects usually don’t mind the short-term bulls and bears rather they focus more on the overall development and expansion of the business.